LIBO
麗寶新藥生物科技股份有限公司
LIBO is a Taiwan Emerging Stock Board biotechnology company; its most advanced asset is LIB-101 (Phase 2 ongoing, Diffuse large B-cell lymphoma), as of 2026-11-01.
Pipeline
| Asset | Target / mechanism | Stage | Indication | Region | Source date | Source |
|---|---|---|---|---|---|---|
| LIB-101 | Recombinant IL-12 glycoprotein | Phase 2 ongoing | Diffuse large B-cell lymphoma | — | 2026-05-25 | Company disclosure |
Key events
- LIB-101 emergency-radiation research collaboration with Fukushima Medical University (company disclosure)
- LIBO corporate development update (company disclosure)